Novo Nordisk to initiate study assessing CagriSema vs Tirzepatide
Browse by category



Fractyl expands ERASE Task Force to study underlying GLP-1-based pancreatic gene therapy for T2DM

AstraZeneca enters obesity market with $2b deal for GLP-1 candidate


Lilly's Mounjaro (tirzepatide) receives UK marketing authorisation for weight management


FDA approves Lilly's Zepbound (tirzepatide) for chronic weight management


Endo Tools Therapeutics announces recruitment of first patient in ESTIME clinical trial


Biolexis Therapeutics launches Metabolexis to develop novel oral medicines for obesity and T2DM


Viking Therapeutics completes of enrolment in VENTURE Trial for GLP-1/GIP receptor agonist VK2735


GE HealthCare and Novo Nordisk to collaborate on peripheral focused ultrasound for T2DM and obesity


First commercial use of Levita Magnetics’ MARS Surgical System